TCR2 Therapeutics (TCR2 Therapeutics) Ending Cash Position : $15.60 Mil (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

What is TCR2 Therapeutics Ending Cash Position?

TCR2 Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2023 was $15.60 Mil.

TCR2 Therapeutics's quarterly Ending Cash Position declined from Sep. 2022 ($55.16 Mil) to Dec. 2022 ($33.90 Mil) and declined from Dec. 2022 ($33.90 Mil) to Mar. 2023 ($15.60 Mil).

TCR2 Therapeutics's annual Ending Cash Position increased from Dec. 2020 ($94.74 Mil) to Dec. 2021 ($223.72 Mil) but then declined from Dec. 2021 ($223.72 Mil) to Dec. 2022 ($33.90 Mil).

TCR2 Therapeutics Ending Cash Position Historical Data

The historical data trend for TCR2 Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TCR2 Therapeutics Ending Cash Position Chart

TCR2 Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Ending Cash Position

Get a 7-Day Free Trial

47.96

65.71

94.74

223.72

33.90

TCR2 Therapeutics Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Ending Cash Position	Get a 7-Day Free Trial															75.28	45.36	55.16	33.90	15.60

TCR2 Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TCR2 Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	223.72	+	-189.822
	=	33.90

TCR2 Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	33.898	+	-18.3
	=	15.60

TCR2 Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of TCR2 Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

TCR2 Therapeutics (TCR2 Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCR2 Therapeutics Inc (NAS:TCRR) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Binney Street, Suite 710, Cambridge, MA, USA, 02142

Website

https://www.tcr2.com

TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which are effective in patients with solid tumors.

Executives

Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Ansbert Gadicke	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Mpm Asset Management Llc	10 percent owner	399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Shawn Tomasello	director	C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Priti Hegde	director	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Rosemary Harrison	officer: Chief Business & Strategy	C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Garry E Menzel	director, officer: President & CEO	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Peter Olagunju	officer: Chief Technical Officer	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Alfonso Quintas Cardama	officer: Chief Medical Officer	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Angela Justice	officer: Chief People Officer	310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Eric Sullivan	officer: Chief Financial Officer	GOODWIN PROCTER LLP, 53 STATE ST, BOSTON MA 02109
Mayur Ian Somaiya	officer: Chief Financial Officer	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Axel Hoos	director	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142